Pricing, Profits and Progress: Pharma’s Post-COVID Priorities
pharmaphorum
JUNE 10, 2021
The fundamental misconception among the public, the media and even some lawmakers is that higher drug list prices are the result of drug manufacturers being in a monopolistic position to endlessly raise prices on critical drugs like insulin and then rake in big profits. Is the Middleman at Fault?
105 
Let's personalize your content